Loading...
Market
Market price of Kebilidi in the US by June 30, 2025?
2
Resolution / Starting Odds
Under $500,000 • 25%
$500,000 - $750,000 • 25%
$750,001 - $1,000,000 • 25%
Over $1,000,000 • 25%
PTC Therapeutics' official pricing announcements or healthcare pricing databases
Story
FDA Approves PTC Therapeutics' Brain-Delivered Gene Therapy Kebilidi for AADC Deficiency
Nov 14, 2024, 01:23 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy, marketed under the name Kebilidi, is the first brain-delivered gene therapy approved in the United States. The approval was granted following an open-label study involving 13 patients and the use of historical control data.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Remain within +/- 10% • 25%
Increase by 20% or more • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Above $30 • 25%
$20-$30 • 25%
$10-$20 • 25%
Below $10 • 25%
